Viking Therapeutics (VKTX)
28.20
-1.58 (5.31%)
Upcoming Events
Latest Headlines
Form 4 Viking Therapeutics, For: Jun 01 Filed by: Chen Hubert C
June 3, 2026 7:45 PM - SEC Filing
Form 3 Viking Therapeutics, For: Jun 01 Filed by: Chen Hubert C
June 3, 2026 7:44 PM - SEC Filing
Lake Street Starts Viking Therapeutic (VKTX) at Buy
May 28, 2026 7:38 AM - StreetInsider
Truist Securities Assumes Viking Therapeutic (VKTX) at Buy
May 27, 2026 6:08 AM - StreetInsider
Form 8-K Viking Therapeutics, For: May 19
May 26, 2026 4:48 PM - SEC Filing
Viking Therapeutics to Participate at Upcoming Investor Conferences
May 21, 2026 7:05 AM - PR NewsWire
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
May 13, 2026 8:33 AM - StreetInsider
Viking Therapeutics presents obesity drug trial results at conference
May 12, 2026 7:05 AM - StreetInsider
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
May 12, 2026 7:05 AM - PR NewsWire
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
May 5, 2026 7:05 AM - PR NewsWire
Form SCHEDULE 13G Viking Therapeutics, Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 2:22 PM - SEC Filing
Viking Therapeutic (VKTX) PT Lowered to $95 at Morgan Stanley
April 30, 2026 7:59 AM - StreetInsider
Form 10-Q Viking Therapeutics, For: Mar 31
April 30, 2026 6:14 AM - SEC Filing
Viking Therapeutics (VKTX) Misses Q1 EPS by 35c
April 29, 2026 4:16 PM - StreetInsider
Form 8-K Viking Therapeutics, For: Apr 29
April 29, 2026 4:06 PM - SEC Filing
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
April 29, 2026 4:05 PM - PR NewsWire
Raymond James on Viking Therapeutic (VKTX): 'Our analysis of this dataset suggests semaglutide does not have a lean body mass preservation advantage'
April 24, 2026 6:36 AM - StreetInsider
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
April 23, 2026 6:19 AM - StreetInsider
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
April 22, 2026 4:35 PM - PR NewsWire
Viking Therapeutics to Participate at Upcoming Investor Conferences
April 10, 2026 7:30 AM - PR NewsWire
Form ARS Viking Therapeutics, For: Dec 31
April 1, 2026 4:17 PM - SEC Filing
Form DEFA14A Viking Therapeutics,
April 1, 2026 4:16 PM - SEC Filing
Form DEF 14A Viking Therapeutics, For: May 19
April 1, 2026 4:15 PM - SEC Filing
Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
March 31, 2026 6:35 AM - StreetInsider
Form SCHEDULE 13G/A Viking Therapeutics, Filed by: VANGUARD GROUP INC
March 27, 2026 1:53 PM - SEC Filing
William Blair stays Outperform on Viking Therapeutic (VKTX) amid 'torrid pace' in advancing VK2735
March 26, 2026 10:56 AM - StreetInsider
Morgan Stanley on Viking Therapeutics (VKTX): 'encouraged' by execution, patient demand
March 26, 2026 8:13 AM - StreetInsider
Viking Therapeutics completes enrollment in phase 3 obesity trial
March 26, 2026 7:05 AM - StreetInsider
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
March 26, 2026 7:05 AM - PR NewsWire
Wolfe Research Starts Viking Therapeutic (VKTX) at Peerperform
March 26, 2026 5:33 AM - StreetInsider
Viking Therapeutics (VKTX) call put ratio 5.6 calls to 1 put with a focus on March 27 weekly calls
March 25, 2026 6:18 AM - StreetInsider
Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this year"
March 12, 2026 12:48 PM - StreetInsider
Form 4 Viking Therapeutics, For: Mar 10 Filed by: Aubuchon Neil William
March 10, 2026 6:21 PM - SEC Filing
Full Article List
